Corcept loses patent fight with Teva over Cushing’s syndrome drugnews2024-01-02T18:59:12+00:00January 2nd, 2024|Endpoints News|
Longboard stock soars on heels of positive topline data for seizure medicationnews2024-01-02T18:46:12+00:00January 2nd, 2024|Endpoints News|
Omeza warned over poor manufacturing conditions; MiMedx in FDA talks over Axiofill reclassificationnews2024-01-02T17:55:30+00:00January 2nd, 2024|Endpoints News|
MarketingRx roundup: Gilead, Pfizer sponsor divas’ benefit concert; Amgen joins Rose Paradenews2024-01-02T17:14:38+00:00January 2nd, 2024|Endpoints News|
Anavex’s experimental drug fails Rett syndrome study, stock fallsnews2024-01-02T16:24:51+00:00January 2nd, 2024|Endpoints News|
AstraZeneca’s $40M deal with Allorion; Apollo raises $33M; Xoma’s stock buybacknews2024-01-02T15:59:22+00:00January 2nd, 2024|Endpoints News|
Brand drug naming faces challenges in emerging categories, expert saysnews2024-01-02T15:13:39+00:00January 2nd, 2024|Endpoints News|
Roche makes ADC deal with China’s MediLink Therapeutics for $50M upfrontnews2024-01-02T15:07:08+00:00January 2nd, 2024|Endpoints News|
Sanofi, Regeneron and AbbVie lead pharma TV advertisers in booming 2023news2024-01-02T14:07:48+00:00January 2nd, 2024|Endpoints News|
Shunned by insurers, digital therapeutics startups look for other ways to get paidnews2024-01-02T13:00:39+00:00January 2nd, 2024|Endpoints News|
